• Anixa treated a second patient in cohort 5 of its Phase 1 FSHR-targeted CAR-T trial for recurrent ovarian cancer.
• Results have not been presented; the update centers on enrollment progress and interim observations from the ongoing study.
• Management cited multiple patients living beyond one year post-treatment, including one beyond two years, in a heavily pre-treated population.
• No dose-limiting toxicities have been observed so far across cohorts, including the first patient treated at the highest dose level.
• The read-through supports continued dose escalation and could shape partnering interest for a solid-tumor CAR-T program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610010835PR_NEWS_USPR_____LA61453) on October 01, 2026, and is solely responsible for the information contained therein.